A Randomized Trial Comparing the Efficacy and Safety of Secukinumab with Tofacitinib in the Treatment of Moderate to Severe Hidradenitis Suppurativa in Chinese Patients
Conditions
Interventions
- DRUG: Secukinumab 300 MG; Tofacitinib 11mg
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborators
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]